Evaluating Conversational Artificial Intelligence for Depression Management

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-85
SponsorGeorge Mason University

About this trial

The goal of this clinical trial is to evaluate how a conversational method of collecting medical history affects patients' perceptions and experiences compared to clinical care as usual. This conversational AI intake system collects medical history information, can be completed by participants at home, and do not disrupt routine clinical care.

The primary questions this study aims to answer are:

1\) Does conversational intake affect patients' perceptions of empathy during their clinical interactions?

This will be a prospective study that follows a cohort of participants for four (4) months after engaging with the AI intake system. Because each participant serves as his/her own control, both comparators will be administered within-subject, and the order of exposure (AI intake vs. usual care) will be randomized to minimize sequence effects.

After completing the AI intake method, participants will rate their experience, particularly in terms of empathy and compare it to their usual interactions with their own clinicians.

Eligibility criteria

Qualifiers

Participant is between 18 to 85 years old.

Participant has been, or are likely to be, diagnosed with moderate to severe Major Depressive Disorder without signs of bipolar depression.

Participant is not in active suicidal crisis and do not face imminent risk of suicide within the next 3 hours.

Participant is not pregnant or seeking to be pregnant.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Conversational AI system vs Usual Care

Treatment groups

130 Participants
are divided into 1 treatment group

Sponsors and collaborators

George Mason University

Lead sponsor

Patient-Centered Outcomes Research Institute

Collaborator